Background and aims
===================

Non alcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease in Western countries affecting approximately 15--30% of the general population \[[@b1-cm-89-82],[@b2-cm-89-82]\]. NAFLD prevalence is growing up to 75--90% when NAFLD is associated with type 2 diabetus mellitus (T2DM) and obesity \[[@b3-cm-89-82]\]. The disease spectrum includes nonalcoholic fatty liver, nonalcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma. NAFLD has become a major and emerging cause of liver disease in worldwide, responsible for increased overall and liver-related mortality and significant increase in the health care costs \[[@b4-cm-89-82],[@b5-cm-89-82]\]. It will represent the major underlying etiology for liver transplantation in Western countries by 2020. NAFLD is frequently associated with visceral obesity, dyslipidemia, insulin resistance (IR), and T2DM and may represent another component of the metabolic syndrome (MetS) \[[@b6-cm-89-82]\]. Presence of MetS and obesity were independent factors associated to NASH. Leptin levels and body mass index (BMI) were higher in patients with advanced hepatic fibrosis \[[@b7-cm-89-82]\].

The gold standard technique for identifying NAFLD is liver biopsy but is not feasible to perform an invasive and costly procedure in such a large number of patients. It is important to identify patients with NAFLD using simple methods, in order to be referred for ultrasonography or liver biopsy and to identify those at highest risk of NASH or advanced liver disease. Clinical risk factors, such as the presence of the MetS and its features, as well as emerging biomarkers can help select NAFLD patients. The "fatty Liver index" (FLI) is a surrogate steatosis biomarker developed in a cohort of patients from the general population with ultrasound-diagnosed hepatic steatosis (HS) \[[@b8-cm-89-82]\].

FLI is based on aggregate scores from different anthropometric and metabolic parameters: BMI, waist circumference (WC), triglycerides (TGL) and gammaglutamyl-transferase (GGT). FLI represents an accurate and easy to obtain algorithm for NAFLD, useful in retrospective series of patients \[[@b9-cm-89-82]\]. It is considered a screening tool to identify NAFLD in patients with cardiometabolic risk factors where ultrasound is unavailable. FLI is able to discriminate between the absence and the presence of steatosis showing good diagnostic performance in detecting NAFLD in several population studies \[[@b9-cm-89-82],[@b10-cm-89-82],[@b11-cm-89-82],[@b12-cm-89-82]\]. The FLI has been associated with reduced insulin sensitivity, risk of type 2 diabetes, accelerated atherosclerosis and cardiovascular risk \[[@b13-cm-89-82]\]. It is associated with all-cause and cardiovascular mortality in patients at high risk of coronary artery disease \[[@b14-cm-89-82]\]. The adequacy of FLI as a quantitative biomarker of steatosis remains unknown \[[@b9-cm-89-82]\].

NAFLD risk factors in non-diabetic patients was largely analyzed. The prevalence of NAFLD and its risk factors in particular high-risk groups of steatosis patients (like T2DM) was poorly evaluated in Romania. The objective of the present study was to establish the prevalence of NAFLD-FLI in our population and to analyze the association between NAFLD-FLI and metabolic risk factors in patients with T2DM. Specifically, we aimed at studying predictors of steatosis in T2DM patients and to analyze the association with anthropometric measurements and biochemical parameters.

Methods
=======

1. Patients and methods
-----------------------

We retrospectively enrolled 381 type 2 diabetic outpatients who regularly attended a Consulting Clinic in Cluj, Romania between 2014--2015. We previously excluded patients who had other causes of chronic liver disease (autoimmune hepatitis, hemochromatosis, Wilson disease, alpha 1 antitrypsin deficiency), viral B and C hepatitis or HIV infection, alcohol consumption greater than 40 g/day. The study protocol was in accordance with the ethical guidelines of the Declaration of Helsinki and approved by the local Ethics Committee.

2. Clinical and laboratory assessment
-------------------------------------

All 381 patients underwent a complete clinical and anthropometric evaluation, including: age, sex, weight, height, waist and hip circumference, systolic and diastolic blood pressure. Information on medical history, alcohol consumption, smoking and use of medications was obtained from all patients by interviews during medical examinations.

BMI was calculated by dividing weight in kilograms by the square of height in meters. Overweight/obesity was diagnosed when BMI was ≥25.0 kg/m^2^, according to the 1999 WHO criteria \[[@b15-cm-89-82]\]. Blood pressure was measured at the right upper arm after patient had been seated quietly for at least 5 minutes. Subjects were considered to have hypertension if their blood pressure was ≥140/85 mmHg according to the European Society of Cardiology (ESC) and European Society of Hypertension (ESH) or if they were taking any anti-hypertensive drugs. Venous blood was drawn in the morning after an overnight fast. We determined by standard laboratory procedures liver function tests, total cholesterol, HDL cholesterol, TGL, apo A and apo B, high-sensitivity C-reactive protein, blood creatinine level, fasting blood glucose, and HbA1c. Plasmatic insulin levels were available in only 208 subjects. Insulin resistance was determined by the homeostasis model assessment (HOMA-IR) method using the following formula: HOMA-IR = \[fasting glucose (mmol/l) × fasting insulin (μUI/ml)\]/22.5. IR was defined as HOMA-IR N 2.7 according to previous publications for European countries \[[@b16-cm-89-82]\]. Viral serology for hepatitis C and B, antimitochondrial, antinuclear, and anti-smooth muscle antibodies were assessed in order to exclude other causes of chronic liver disease.

NAFLD was defined by a non-invasive marker for liver steatosis, fatty liver index (FLI), an algorithm based on BMI, WC, TGL and GGT (8). FLI ≥60 indicates the presence of NAFLD. A stratification of NAFLD was made in tertiles I (FLI=60--75); II (FLI=75--90); III (FLI \>90).

3. Hepatic ultrasonography (US)
-------------------------------

Hepatic US was performed in all patients after 12 hours fasting, by a single experienced radiologist by a high-resolution B-mode ultrasonography with a 5 MHz transducer (Philips HD11 XE ultrasound system). Each subject was examined in the supine and left lateral positions with the right arm raised above the head, during quiet inspiration. Hepatic steatosis (HS) was diagnosed using well-established criteria, including the hepatorenal echo contrast, liver parenchymal brightness, deep beam attenuation, and vascular blurring.

4. Statistical analysis
-----------------------

Descriptive results have been expressed as means ±SD. Comparisons between groups according to the presence of NAFLD-FLI, were performed using Student's t-test for normally distributed continuous variables and the Mann-Whitney *U* test for asymmetric continuous variables. Frequency distributions of categorical data have been compared using χ^2^ tests and Fisher's exact tests. Correlations between quantitative variables have been investigated using Spearman's correlation coefficient rho. To identify independent variables associated with NAFLD-FLI, we used multiple linear regression analysis. Then, NAFLD-FLI has been dichotomized based on a 60 cut-off value \[[@b8-cm-89-82]\], and multiple logistic regression analyses have been performed using iterative selection of covariates for optimal prediction of NAFLD-FLI being higher than 60. Probability levels lower than 0.05 were considered statistically significant. All analyses have been performed using IBM SPPS 21 MacOS statistical software (Chicago IL).

Results
=======

Three hundred and eighty-one T2DM patients were enrolled in this study (132 females and 249 males), with a mean age of 56.3 years (range, 26--78 years). According to the results obtained by FLI, the 381 patients were divided into 2 groups: with NAFLD-FLI (79%) and without NAFLD-FLI (21%). The prevalence of NAFLD was 79%. Clinical and biochemical characteristics of patients grouped according to NAFLD-FLI status are presented in [Table I](#tI-cm-89-82){ref-type="table"}. We excluded from [Table I](#tI-cm-89-82){ref-type="table"} the parameters used in the FLI algorithm (BMI, WC, TGL and GGT).

NAFLD-FLI was correlated with hepatic steatosis evaluated by ultrasound (r=0.28; p\<0.001) suggesting that FLI had been a good method for evaluating NAFLD in our T2DM population.

The percentage of oral hypoglycemic users was 83.9% and patients treated with insulin was 26.9%. Coronary artery disease (CAD) was present in 26.9%, peripheral artery disease in 19.2% and metabolic syndrome in 85.3.2% of the studied sample. In this population, 38% subjects were treated with statins, and 23.1% were treated with fibrate therapy. NAFLD-FLI was correlated with age (r= −0.14; p=0.007), sex (r=0.20; p\<0.001), LDL cholesterol (r=0.12; p=0.032), HDL cholesterol (r= −0.13; p=0.015), ALAT (r=0.20; p\<0.001) and ASAT (r=0.19; p\<0.001). ALAT was normal (\< 35 U in women and \< 50 U in men) in 279 patients of 381. Interestingly, we found that 73.8% of patients with normal ALAT had NAFLD (defined as FLI \>60), 60.9% (170 patients) had FLI \>75 and 33% (93patients) had FLI \>90. In patients with NAFLD-FLI the prevalence of obesity was 80% (307 patients of 381). [Table II](#tII-cm-89-82){ref-type="table"} presents three models of multiple regression analysis, with independent variables that contextually predicted the dependent variable NAFLD-FLI. Sex, ALAT and LDL-cholesterol were independent predictors of NAFLD-FLI. We excluded from our analysis predictors that could have interfered with the parameters used in the FLI score algorithm.

For a subset of 208 patients, the HOMA-IR score was calculated. After iterative selection of covariates for model optimization, our best logistic regression model included ALAT, HOMA and CAD as independent predictors of NAFLD-FLI ([Table III](#tIII-cm-89-82){ref-type="table"}). During the model optimization process, other investigated predictors and possible confounders did not significantly contribute to the prediction of a NAFLD-FLI being higher than 60.

Discussion
==========

The key findings of the current study may be summarized as follows. Firstly we observed a high prevalence of NADLD-FLI (79%) in subjects with type 2 diabetes, with an increase up to 80% in the elderly over 75 years. The prevalence of NAFLD-FLI was higher in males than in females. In our NAFLD-FLI and T2DM patients, 80% were obese (BMI \>30 Kg/m^2^). Compared with patients without NAFLD-FLI, the subjects with NAFLD-FLI were younger, predominantly male (70.5%), and had higher TC, LDLc, uricemia, higher HOMA-IR values, higher ASAT and ALAT and an increased prevalence of the metabolic syndrome but lower HDLc levels. Indeed, the prevalence of NAFLD has increased rapidly in European population and is estimated to be 20% to 30% \[[@b17-cm-89-82]\]. Previous studies have reported a prevalence of NAFLD that ranges from 7.27% to 23.4% in the non-obese population \[[@b18-cm-89-82]\]. Most studies indicate that NAFLD increases in parallel with that of obesity and diabetes, rising up to 75--90% \[[@b2-cm-89-82],[@b19-cm-89-82]\]. A strong increase of NAFLD has recently been observed especially in adolescents and in older people. In patients with fatty liver, the prevalence of obesity is between 30% and 100%, and that of type 2 diabetes between 10% and 75% \[[@b20-cm-89-82]\].

Secondly, we found that FLI was correlated with HS assessed by US, reinforcing the fact that FLI could be considered a valid tool of NAFLD evaluation in our group of patients. Because of the burden of disease, it is important to identify which patients are most likely to be exposed to NAFLD. It is difficult to perform biopsies on such a large number of patients. For this reason we used FLI for NAFLD diagnosis. In order to enhances the validity of our findings and because our cohort included T2DM patients with traditional coronary risk factors, we used two modalities for diagnosis of HS (US and FLI score for NAFLD).

Thirdly, we found that 73.8% of patients with normal ALAT had NAFLD (FLI \>60), and 33% of them had FLI \>90. Obesity had a high prevalence up to 80% in NAFLD patients. Indeed, it has recently been demonstrated that the prevalence of NAFLD and NASH in patients with T2DM and normal ALAT levels is 50% and 55%, respectively. The prevalence of NAFLD is much higher than previously believed in overweight/obese patients with T2DM and normal aminotransferases and many are at increased risk of NASH \[[@b21-cm-89-82],[@b22-cm-89-82]\]. A recent study indicates that 30% to 60% of patients with biopsy-confirmed NASH have a normal ALAT level \[[@b22-cm-89-82],[@b23-cm-89-82]\]. Elevated level of ALAT had a sensitivity of 45% and specificity of 85% for diagnosis of NAFLD may correlate with IR \[[@b23-cm-89-82]\].

Fourthly, we found that sex, higher HOMA-IR values, higher ALT and LDLc levels were significant and independent factors associated with the presence of NAFLD-FLI in T2DM subjects. Consistent with our findings, previous studies reported that male subjects had higher risk of NAFLD. A possible explanation could be the higher BMI and more accelerating visceral adipose tissue expansion increasing with age. It could facilitate the development of IR and HS by the production of free fatty acid and adipocytokines \[[@b24-cm-89-82]\]. Estrogen could suppress visceral adipose tissue and TG accumulation. A recent study reported that estrogen receptor ligands reduced hepatic TG levels through the inhibition of liver X receptor transcriptional activity in a mouse model \[[@b25-cm-89-82]\]. Dyslipidemia, hyperinsulinemia and IR are common in subjects with NAFLD independently from BMI. IR was associated with disease progression in NAFLD. FLI was correlated with IR as assessed with HOMA-IR independently from the histological grades of steatosis \[[@b26-cm-89-82]\].

This study has some limitations that should be kept in mind. First, this study has a retrospective design that could introduce a bias concerning the selection of patients for hepatic US. Second, NAFLD was defined using FLI, a steatosis biomarker validated against liver US as a simple and performant tool for the detection of fatty liver and the prediction of IR \[[@b9-cm-89-82]\]. A recent study in T2DM patients showed that the performance of FLI (and others surrogate steatosis markers) for the prediction of steatosis was very low \[[@b27-cm-89-82]\]. FLI seems to be insufficiently accurate for the quantification of steatosis and has a limited value for monitoring changes in steatosis induced by pharmacological and nonpharmacological measures. FLI is prone to substantial confounding due to steatohepatitis and advanced fibrosis and had a significant positive but weak-to-moderate correlation with HOMA-IR \[[@b9-cm-89-82]\]. Third, the reference for NAFLD-FLI was considered HS evaluated by US. Hepatic US is widely used in evaluation of NAFLD, because it is safe, noninvasive, and widely available. It is an operator-dependent procedure, with an acceptable sensitivity in relation to the detection of HS (60--94% sensitivity and 66--97% specificity) \[28,29\[. US has a low sensitivity especially for mild steatosis as it detects the steatosis when present in more than 20--30% of hepatocytes \[[@b29-cm-89-82],[@b30-cm-89-82],[@b31-cm-89-82]\]. According to available study data, the positive predictive value in mild steatosis is only 67% at best \[[@b29-cm-89-82]\]. Additionally, it cannot reliably quantify steatosis, an important drawback for the ability to monitor dietary and pharmacological interventions. Liver biopsies (LB) were not available in our subjects. LB is invasive and may result in severe complications but is considered the gold standard technique for identifying NAFLD \[[@b32-cm-89-82]\]. Fourth, we could not completely exclude secondary causes of liver disease and this limitation could have increased the number of included patients.

Conclusions
===========

Our results are in line with those of other studies suggesting that FLI could be useful to identify NAFLD in T2DM patients when US is unavailable. Subjects with T2DM had a high prevalence of NADLD-FLI even when ALAT levels were normal. Our findings showed that sex, ALAT, LDL-cholesterol and IR were significant and independent factors associated with the presence of NAFLD in T2DM subjects.
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###### 

Clinical and biochemical characteristics of diabetic patients grouped according to NAFLD as assessed by fatty liver index (FLI). Since most variables departed significantly from normal distribution, comparisons between groups based on the presence of NAFLD by FLI, were performed using Mann-Whitney U tests for quantitative variables and Fisher's exact tests for categorical data. Data are presented as means ± SD or number. p\<0.05 were considered significant.

  Variable                    With NAFLD-FLI mean±SD (median)   Without NAFLD-FLI mean±SD (median)   P
  --------------------------- --------------------------------- ------------------------------------ --------
  Age (years)                 55.7±8.9                          58.7±8.5                             0.006
  Diabetes duration (years)   5.0 (0.38)                        5.0 (0.29)                           0.22
  SBP (mmHg)                  140 (100, 230)                    150 (100, 200)                       0.75
  DBP (mmHg)                  86 (50, 155)                      86 (65, 107)                         0.3
  TC (mmol/l)                 5.09 (2.8, 16.47)                 4.68 (2.43, 8.30)                    0.006
  HDLc (mmol/l)               1.06±0.43                         1.16±0.46                            0.008
  LDLc (mmol/l)               3.25 (0.57, 10.30)                3.02 (0.86, 5.07)                    0.82
  FPG (mmol/l)                157 (78, 476)                     162.5 (70, 682)                      0.4
  HOMA-IR                     5.38 (0.94, 135)                  2.73 (0.83, 28.92)                   0.0001
  HbA1C                       7.9 (5.1, 15.6)                   7.9 (5, 14.4)                        0.99
  ASAT (units/l)              24.5 (7, 191)                     20 (7, 70)                           0.0001
  ALAT (units/l)              33 (8, 209)                       24.6 (11.4, 135)                     0.0001
  Acid uric (mg/dl)           5.7±1.65                          4.76±1.37                            0.0001

###### 

Multiple regression analysis. Model 1--3: sex, ALAT and LDL-cholesterol are independently correlated with NAFLD.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Model                       Independent variable   Non-standardized Coefficients   Standardized Coefficients Beta   t        P        
  --------------------------- ---------------------- ------------------------------- -------------------------------- -------- -------- -------
  Model 1\                    Age (years)            −0.005                          0.002                            −0.108   −2.135   0.033
  r=0.23\                                                                                                                               
  P\<0.0001                                                                                                                             

  Sex (male/female)           0.162                  0.043                           0.190                            3.740    0.0001   

  Model 2\                    Age (years)            −0.003                          0.002                            −0.069   −1.330   0.184
  r=0.27\                                                                                                                               
  P\<0.0001                                                                                                                             

  Sex (male/female)           0.134                  0.044                           0.157                            3.069    0.002    

  ALAT (U/l)                  0.003                  0.001                           0.151                            2.871    0.004    

  Model 3\                    Age (years)            −0.002                          0.003                            −0.053   −0.933   0.352
  r=0.30\                                                                                                                               
  P\<0.0001                                                                                                                             

  Sex (male/female)           0.145                  0.048                           0.165                            3.009    0.003    

  ALAT (U/l)                  0.003                  0.001                           0.160                            2.848    0.005    

  LDL- cholesterol (mmol/l)   0.041                  0.019                           0.117                            2.197    0.029    
  ---------------------------------------------------------------------------------------------------------------------------------------------

NAFLD = non-alcoholic fatty liver disease, ALAT = alanine aminotransferase, LDL-cholesterol = low density lipoprotein, FLI = fatty liver index.

###### 

Multiple logistic regression analysis: ALAT, HOMA-IR, LDLc and CAD were significant predictors of NAFLD by FLI\>60.

  Model                   Prediction accuracy   Independent variable   B       SE      p       Odds Ratio (OR)   95% CI for OR   
  ----------------------- --------------------- ---------------------- ------- ------- ------- ----------------- --------------- -------
  Model 1                 84.1 %                ALAT (units/l)         0.42    0.16    0.007   1.043             1.011           1.075
  HOMA-IR                 0.135                 0.065                  0.039   1.144   1.007   1.300                             
  Model 2                 84.6%                 ALAT (units/l)         0.046   0.016   0.004   1.047             1.015           1.080
  HOMA-IR                 0.152                 0.067                  0.023   1.164   1.020   1.328                             
  Hypertension (yes/no)   −0.272                0.489                  0.578   0.762   0.292   1.987                             
  CAD (yes/no)            1.476                 0.582                  0.011   4.377   1.400   13.686                            
  Model 3                 85.1%                 ALAT (units/l)         0.045   0.016   0.007   1.046             1.012           1.080
  HOMA-IR                 0.134                 0.065                  0.041   1.143   1.005   1.299                             
  LDLc (mmol/l)           0.420                 0.204                  0.040   1.522   1.020   2.273                             

NAFLD = non-alcoholic fatty liver disease, ALAT = alanine aminotransferase, HOMA-IR = homeostasis model assessment insulin resistance, CAD = coronary artery disease, LDLc = low density lipoprotein cholesterol, FLI = fatty liver index.
